Corvus Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Corvus Pharmaceuticals Inc cash flow-to-debt ratio. Corvus Pharmaceuticals Inc (CRVS) has a Cash Flow-to-Debt Ratio of -1.10x as of June 2026, meaning its operating cash flow of $-15.40 Million could theoretically repay -1% of its total liabilities ($13.95 Million) in one year. Check CRVS cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Corvus Pharmaceuticals Inc (2014–2025)
Cash flow-to-debt ratio of Corvus Pharmaceuticals Inc from 2014 to 2025. Historical debt coverage capacity for Corvus Pharmaceuticals Inc across 12 annual periods. Also explore CRVS shareholders equity momentum to track the company's year-over-year net asset growth rate.
Corvus Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2014–2025)
Corvus Pharmaceuticals Inc cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for Corvus Pharmaceuticals Inc. For the full cash flow conversion analysis, see Corvus Pharmaceuticals Inc (CRVS) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.31x | $-32.80 Million | $9.91 Million | ▼ -372.8% |
| 2024 | -0.70x | $-25.42 Million | $36.34 Million | ▲ +79.9% |
| 2023 | -3.48x | $-23.93 Million | $6.87 Million | ▼ -56.3% |
| 2022 | -2.23x | $-27.02 Million | $12.12 Million | ▲ +25.4% |
| 2021 | -2.99x | $-36.72 Million | $12.29 Million | ▼ -14.9% |
| 2020 | -2.60x | $-34.78 Million | $13.38 Million | ▲ +12.7% |
| 2019 | -2.98x | $-37.32 Million | $12.54 Million | ▲ +42.6% |
| 2018 | -5.19x | $-40.99 Million | $7.90 Million | ▼ -11.7% |
| 2017 | -4.65x | $-46.21 Million | $9.94 Million | ▼ -22.6% |
| 2016 | -3.79x | $-27.86 Million | $7.35 Million | ▼ -4235.3% |
| 2015 | -0.09x | $-11.33 Million | $129.56 Million | ▼ -959.3% |
| 2014 | -0.01x | $-104.73K | $12.69 Million | — |